You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK inhibitor

Showing 1 - 25 of 7,727
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced NSCLC Trial in India (Lorlatinib)

Completed
  • Advanced Non-Small Cell Lung Cancer
  • New Delhi, Delhi, India
  • +11 more
Sep 13, 2022

Solid Tumor, NSCLC Metastatic Trial in Guanzhou (Ensartinib)

Recruiting
  • Solid Tumor
  • Non-Small Cell Lung Cancer Metastatic
  • Guanzhou, Guangdong, China
    Sun yat-sen Univerisity Cancer Center
Nov 22, 2021

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +13 more
Jan 31, 2023

Melanoma Trial in United States (Ensartinib, ALKATI by Customized Nanostring Assay)

Active, not recruiting
  • Melanoma
  • Middletown, New Jersey
  • +3 more
Jan 25, 2022

Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • Orange, California
  • +13 more
Nov 7, 2022

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Recruiting
  • Non Small Cell Lung Cancer
  • anti-PD-1 or anti-PD-L1
  • +2 more
  • Shanghai, China
    Oncology Department, Shanghai Chest Hospital
Jul 26, 2022

Chemotherapy Combined With Immunotherapy or Chemotherapy

Completed
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 9, 2022

NSCLC Trial in Guangzhou (TGRX-326)

Recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 18, 2023

NSCLC Trial in China (Lorlatinib)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Hefei, Anhui, China
  • +20 more
Sep 27, 2021

Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

Not yet recruiting
  • Lung Adenocarcinoma
  • +3 more
  • Serplulimab and Bevacizumab injection
  • (no location specified)
Dec 21, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

Non Small Cell Lung Cancer Metastatic Trial in France (Lorlatinib)

Recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Angers, France
  • +31 more
Apr 12, 2022

NSCLC Trial in Germany (Brigatinib, Tyrosine kinase inhibitor)

Recruiting
  • NSCLC
  • Berlin, Germany
  • +25 more
Nov 10, 2022

Advanced Solid Tumors, NSCLC Trial in United States (Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib))

Completed
  • Advanced Solid Tumors
  • Non-small Cell Lung Cancer
  • Phase I: X-396 (ensartinib)
  • Phase II: X-396 (ensartinib)
  • Duarte, California
  • +13 more
Oct 4, 2021

Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)

Completed
Has Results
  • Lymphoma, Large-Cell, Anaplastic
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 26, 2021

Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Korea, Republic of, United States (Entrectinib)

Completed
  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Orange, California
  • +9 more
Jun 7, 2021

NSCLC Trial in Worldwide (Ribociclib, Ceritinib)

Completed
  • Non-small Cell Lung Cancer
  • Boston, Massachusetts
  • +7 more
Dec 16, 2020

Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic

Recruiting
  • Untreated Advanced NSCLC Patients
  • FISH Identified ALK Fusion Positive or Negative
  • ALK inhibitor
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Jul 31, 2020

Carcinoma, Non-Small-Cell Lung Trial in Worldwide (Lorlatinib)

Recruiting
  • Carcinoma
  • Non-Small-Cell Lung
  • Orange, California
  • +31 more
Dec 6, 2022

NSCLC (NSCLC) Trial in China (Capmatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Xiamen, Fujian, China
  • +18 more
Jan 27, 2023

NSCLC Trial in Shanghai (PLB1003)

Unknown status
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Mar 2, 2020

ALK-positive NSCLC Trial in Jilin (XZP-3621)

Not yet recruiting
  • ALK-positive NSCLC
  • Jilin, Chang Chun, China
    Jilin Province Cancer Hospital
Jul 29, 2022

ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer
  • Dallas, Texas
    UT Southwestern Medical Center
Jan 31, 2023

free Survival and Evaluate Participant Experience for Metastatic

Active, not recruiting
  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung
  • Maynard, Massachusetts
    EmpiraMed, Inc.
Feb 28, 2022